SCHEMBL3580187

SCHEMBL3580187

CCOC(=O)CCNc1ccc(Cl)cc1C(=O)N(CCc1cccc(C(F)(F)F)c1)Cc1ccc(C(C)(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.37
HPGD P15428 1/20 0.37
HSPH1 Q92598 1/20 0.37
CNR1 P21554 1/20 0.37
TRPV4 Q9HBA0 1/20 0.36
THRB P10828 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
MEN1 O00255 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP2C9 P11712 1/20 0.35
ATM Q13315 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CETP P11597 1/20 0.35
MPO P05164 1/20 0.35
F10 P00742 1/20 0.34
LPAR1 Q92633 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583318 0.90 HSPH1 (0.44) LMNAHPGDHSPH1CNR1PTGDR2
SCHEMBL3571600 0.88 LMNA (0.42) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL3570289 0.87 LMNA (0.40) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL3575609 0.85 LMNA (0.43) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL3580626 0.84 LMNA (0.40) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL3586188 0.84 NR3C1 (0.43) LMNAHPGDCNR1
SCHEMBL3580426 0.84 HSPH1 (0.42) LMNAHPGDHSPH1CNR1PTGDR2
SCHEMBL3578904 0.83 LMNA (0.44) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL3585675 0.83 LIPC (0.46) LMNAHPGDHSPH1CNR1MEN1
SCHEMBL4612209 0.83 F10 (0.34) LMNACNR1SMN1; SMN2F10LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC LMNA 1337/4885HPGD 1361/4885HSPH1 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.